Bayer Grants4Apps® Dealmaker Berlin 2017

Bayer Grants4Apps® is calling all mature teams, startups and companies that have a solution ready to go. The new Dealmaker is all about quality facetime between you and Grants4Apps' experts for one full day. If there is a match, you will be invited to Berlin to pitch your solution, discuss collaboration options and close a deal. Find out, if there is a mutual interest to start a bigger journey.

Grants4Apps team has put together specific challenges, applicants are asked to address one or multiple of these challenges below. However, the team is also open for other solutions that help healthcare providers or patients, as well as products dedicated to preventing or diagnosing diseases or improving pharmaceutical processes.

The Challenges

Hemophilia

  • Empower hemophilia (bleeding disease) patients to individually adjust their treatment regimen to lead active lives.

Women's Health

  • Enabling earlier diagnosis of endometriosis.
  • Enhancing intrauterine device insertion training for providers.
  • Providing effective contraceptive counseling (face to face, remote or automated).
  • Improving comfort and experience during intrauterine device insertion for both providers & patients.
  • Simplifying the thread/placement check post-insertion of intrauterine devices.

Pulmonology

  • Improve identification of Chronic Thromboembolic Pulmonary Hypertension (CTEPH) patients.
  • Improve adherence for an oral pulmonary hypertension treatment.
  • Innovative and efficient concepts for training staff to use a drug and device combination product in an intensive care unit setting.
  • Create awareness for limited outcome of standard of care treatment for pneumonia in the hospital.

Ophthalmology

  • Remote/mobile screening for Diabetic Retinopathy.
  • Remote monitoring of patients treated with anti-Vascular Endothelial Growth Factors (VEGFs).
  • Utilizing real-world evidence (RWE) to predict the need for anti-Vascular Endothelial Growth Factors (VEGFs)-injections.

Nephrology

  • Monitoring of chronic kidney disease (CKD).
  • Diagnosis of acute kidney injury.

Artificial Intelligence

  • Prediction of combination therapies for cancer.
  • Extract compound structures and Structure-Activity Relationship (SAR) data from patents.
  • Computer-assisted identification of new compounds for protein targets.
  • Develop analysis tool for in vivo experiments.

Data Analytics

  • Data analysis tools to systematically identify worldwide activities in Research & Development.
  • Deep Learning Research Services for health and life science data.
  • Transforming Electronic Health Records (EHR) data to analysis data sets.
  • Analyze drug labels to generate new insights.
  • Develop efficient analysis of large scientific literature corpi to generate insights.
  • How to implement prediction algorithms in hospital information systems.
  • Social Media use in pharma.

Clinical Trials

  • Patient identification and recruitment for clinical trials.
  • Improving the patient experience in clinical trials.
  • Develop a mobile platform for patients to report their health condition parameters.
  • Adherence improvement in (clinical trials OR) real life.

Submission deadline: 30 June 2017

For further information, please visit:
https://www.grants4apps.com/berlin/program/dealmaker-berlin-2017/

About Grants4Apps®
We connect health startups with industry experts and help the best talents to thrive within the digital healthcare universe. We are looking for startups beyond the ideation phase developing health technology or IT solutions that can connect and empower patients or healthcare stakeholders.

There are no boundaries to creativity!

Most Popular Now

In wine, there's health: Low levels of alcohol goo…

While a couple of glasses of wine can help clear the mind after a busy day, new research shows that it may actually help clean the mind as well. The new study, which appe...

Sanofi to acquire Ablynx for €3.9 Billion

Sanofi and Ablynx, a biopharmaceutical company engaged in the discovery and development of Nanobodies®, entered into a definitive agreement under which Sanofi will offer ...

Repurposed drug found to be effective against Zika…

In both cell cultures and mouse models, a drug used to treat Hepatitis C effectively protected and rescued neural cells infected by the Zika virus - and blocked transmiss...

Interim publications of randomized trials make new…

Early results from randomized trials are sometimes published before the trial is completed. The results of such interim publications may generate a great deal of interest...

More stroke patients may receive crucial treatment…

More patients could be eligible for critical treatments to remove or dissolve blood clots that cause strokes, according to a new treatment guideline issued by the America...

Drug trial protocol redactions by industry sponsor…

New research published by the Journal of the Royal Society of Medicine exposes the extent of redactions in protocols for industry-sponsored randomised drug trials. Trial ...

Advanced Accelerator Applications receives FDA ap…

Novartis AG (NYSE: NVS) announced that Advanced Accelerator Applications, a subsidiary of Novartis Groupe S.A., has received US Food and Drug Administration (FDA) approva...

Blood vessel-on-a-chips show anti-cancer drug effe…

Researchers at the Institute of Industrial Science (IIS), the University of Tokyo, CNRS and INSERM, report a new organ-on-a-chip technology for the study of blood vessel ...

Guidelines extended to improve the use of feedback…

Researchers have recommended changes to international guidelines used in the development of clinical trials in an effort to gain information about the impact of the treat...

Roche reports good results in 2017

In 2017, Group sales rose 5% to CHF 53.3 billion. Core operating profit grew 3% and Core EPS increased 5%, reflecting the good underlying business performance. On an IFRS...

Brilinta significantly reduces CV events and coron…

AstraZeneca today announced results from a new sub-analysis of the Phase III PEGASUS-TIMI 54 trial, demonstrating a risk reduction of 19% in MACE (the composite of CV dea...

FDA approves new treatment for certain digestive t…

The U.S. Food and Drug Administration today approved Lutathera (lutetium Lu 177 dotatate) for the treatment of a type of cancer that affects the pancreas or gastrointesti...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]